Suppr超能文献

肝细胞癌的放射治疗:新适应症及未来研究方向

Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.

作者信息

Ohri Nitin, Dawson Laura A, Krishnan Sunil, Seong Jinsil, Cheng Jason C, Sarin Shiv K, Kinkhabwala Milan, Ahmed Mansoor M, Vikram Bhadrasain, Coleman C Norman, Guha Chandan

机构信息

Department of Radiation Oncology (NO, CG) and Montefiore-Einstein Center for Transplantation (MK), Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada (LAD); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (SK); Department of Radiation Oncology, Yonsei University Hospital, Seoul, North Korea (JS); Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (JCC); Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India (SKS); Molecular Radiation Therapeutics Branch (MMA) and Clinical Radiation Oncology Branch (BV), Radiation Research Program (CNC), National Cancer Institute, National Institutes of Health, Bethesda, MD.

出版信息

J Natl Cancer Inst. 2016 Jul 4;108(9). doi: 10.1093/jnci/djw133. Print 2016 Sep.

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide; its incidence is increasing in the United States. Depending on disease extent and underlying liver status, patients may be treated with local, locoregional, and/or systemic therapy. Recent data indicates that radiotherapy (RT) can play a meaningful role in the management of HCC. Here, we review published experiences using RT for HCC, including the use of radiosensitizers and stereotactic RT. We discuss methods for performing preclinical studies of RT for HCC and biomarkers of response. As a part of the HCC Working Group, an informal committee of the National Cancer Institute's Radiation Research Program, we suggest how RT should be implemented in the management of HCC and identify future directions for the study of RT in HCC.

摘要

肝细胞癌(HCC)是全球癌症死亡的主要原因;其发病率在美国呈上升趋势。根据疾病范围和潜在肝脏状况,患者可接受局部、局部区域和/或全身治疗。最近的数据表明,放射治疗(RT)在HCC的管理中可以发挥重要作用。在此,我们回顾了使用RT治疗HCC的已发表经验,包括放射增敏剂和立体定向RT的使用。我们讨论了进行HCC RT临床前研究的方法以及反应生物标志物。作为美国国立癌症研究所放射研究计划的一个非正式委员会——HCC工作组的一部分,我们建议RT应如何在HCC管理中实施,并确定HCC RT研究的未来方向。

相似文献

1
Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.
J Natl Cancer Inst. 2016 Jul 4;108(9). doi: 10.1093/jnci/djw133. Print 2016 Sep.
2
Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities.
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):22-32. doi: 10.1016/j.ijrobp.2012.08.043. Epub 2012 Dec 6.
3
Radiosensitizers in hepatocellular carcinoma.
Semin Radiat Oncol. 2011 Oct;21(4):303-11. doi: 10.1016/j.semradonc.2011.05.008.
4
5
Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization.
Int J Cancer. 2001 Aug 20;96(4):243-52. doi: 10.1002/ijc.1022.
6
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies.
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818790217. doi: 10.1177/1533033818790217.
7
Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?
Yonsei Med J. 2018 Oct;59(8):912-922. doi: 10.3349/ymj.2018.59.8.912.
8
Radiation therapy for hepatocellular carcinoma: from palliation to cure.
Cancer. 2006 Apr 15;106(8):1653-63. doi: 10.1002/cncr.21811.
9
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities.
Dig Dis Sci. 2019 Apr;64(4):1008-1015. doi: 10.1007/s10620-019-05539-0.
10
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.
Cancer J. 2016 Jul-Aug;22(4):296-301. doi: 10.1097/PPO.0000000000000201.

引用本文的文献

2
A nomogram for prognostic prediction and for therapeutic decision making of elderly HCC patients.
BMC Gastroenterol. 2025 Apr 15;25(1):257. doi: 10.1186/s12876-025-03823-0.
7
Prognostic model and ceRNA network of m7G- and radiosensitivity-related genes in hepatocellular carcinoma.
Heliyon. 2024 Apr 24;10(9):e29925. doi: 10.1016/j.heliyon.2024.e29925. eCollection 2024 May 15.
9
RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives.
Nat Rev Gastroenterol Hepatol. 2024 Apr;21(4):267-281. doi: 10.1038/s41575-023-00884-y. Epub 2024 Jan 19.
10
TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.
Oncogene. 2024 Feb;43(9):682-692. doi: 10.1038/s41388-023-02935-9. Epub 2024 Jan 12.

本文引用的文献

1
Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
J Clin Oncol. 2016 Feb 10;34(5):452-9. doi: 10.1200/JCO.2015.61.4925. Epub 2015 Nov 30.
2
Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Gastroenterology. 2015 Jun;148(7):1383-91.e6. doi: 10.1053/j.gastro.2015.02.055. Epub 2015 Mar 4.
3
The yin and yang of evasion and immune activation in HCC.
J Hepatol. 2015 Jun;62(6):1420-9. doi: 10.1016/j.jhep.2015.02.038. Epub 2015 Feb 27.
5
Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
Oncotarget. 2015 Jan 20;6(2):1020-30. doi: 10.18632/oncotarget.2741.
7
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8.
8
Epigenetic biomarkers in liver cancer.
Methods Mol Biol. 2015;1238:65-76. doi: 10.1007/978-1-4939-1804-1_4.
9
10
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.
Cell Mol Immunol. 2015 Jul;12(4):474-82. doi: 10.1038/cmi.2014.102. Epub 2014 Nov 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验